Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis
- 7 December 2023
- journal article
- research article
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 169, 107815
Abstract
No abstract availableKeywords
Funding Information
- National Key Research and Development Program of China (2021YFE0206400)
- Fundamental Research Funds for the Central Universities (226-2022-00220)
- National Natural Science Foundation of China (22373062, 82204279)
This publication has 49 references indexed in Scilit:
- Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung CancerClinical Cancer Research, 2012
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung CancersScience Translational Medicine, 2012
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper MutantCancer Cell, 2011
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK InhibitorsNew England Journal of Medicine, 2010
- Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domainBiochemical Journal, 2010
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- Comparison of multiple Amber force fields and development of improved protein backbone parametersProteins: Structure, Function, and Bioinformatics, 2006
- The Amber biomolecular simulation programsJournal of Computational Chemistry, 2005
- Development and testing of a general amber force fieldJournal of Computational Chemistry, 2004
- Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database ScreeningJournal of Medicinal Chemistry, 2004